Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity.

× No keyword cloud information.

21 in total

Review 1. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma.

Authors: Daneng Li; Eileen M O'Reilly
Journal: Semin Oncol Date: 2014-12-09 Impact factor: 4.929

2. Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay.

Authors: Haruko Ogawa; Uri Galili
Journal: Glycoconj J Date: 2006-11-18 Impact factor: 2.916

3. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.

Authors: Ussama Abdel-Motal; Shixia Wang; Shan Lu; Kim Wigglesworth; Uri Galili
Journal: J Virol Date: 2006-07 Impact factor: 5.103

4. Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells.

Authors: Ying Qiu; Ming-Bao Xu; Mark M Yun; Yi-Zhong Wang; Rui-Ming Zhang; Xing-Kai Meng; Xiao-Hui Ou-Yang; Sheng Yun
Journal: World J Gastroenterol Date: 2011-12-28 Impact factor: 5.742

5. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.

Authors: J G Schoenecker; R K Hauck; M C Mercer; W Parker; J H Lawson
Journal: J Clin Immunol Date: 2000-11 Impact factor: 8.317

6. Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria.

Authors: Karla J Posekany; H Keith Pittman; John F Bradfield; Carl E Haisch; Kathryn M Verbanac
Journal: Infect Immun Date: 2002-11 Impact factor: 3.441

7. Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity.

Authors: Ussama M Abdel-Motal; Kim Wigglesworth; Uri Galili
Journal: Cancer Immunol Immunother Date: 2009-01-28 Impact factor: 6.968

Review 8. Bridging innate and adaptive antitumor immunity targeting glycans.

Authors: Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal: J Biomed Biotechnol Date: 2010-06-15

9. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.

Authors: Sourav Sarkar; Alex C D Salyer; Katherine A Wall; Steven J Sucheck
Journal: Bioconjug Chem Date: 2013-03-08 Impact factor: 4.774

10. Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma.

Authors: Mark R Albertini; Erik A Ranheim; Cindy L Zuleger; Paul M Sondel; Jacquelyn A Hank; Alan Bridges; Michael A Newton; Thomas McFarland; Jennifer Collins; Erin Clements; Mary Beth Henry; Heather B Neuman; Sharon Weber; Giles Whalen; Uri Galili
Journal: Cancer Immunol Immunother Date: 2016-05-20 Impact factor: 6.968